As a longtime critic of Eli Lilly's (NYSE: LLY )
R&D and clinical trial management, I can't say I was surprised to
see the news that yet another phase 3 drug candidate failed -- this time
it was edivoxetine in depression. That stings all the more with recent
late-stage failures for drugs targeted at breast cancer, Alzheimer's,
and schizophrenia. It also serves to highlight that the depression
market is a challenging one, making the recent launch of a new and
different depression drug from H. Lundbeck (NASDAQOTH: HLUYY ) all the more interesting.
Click the link to read more:
Mood-Altering News From the Pharma Space
No comments:
Post a Comment